Showing results (101-110 of 320) with videos related to
Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancerJ C Newby, S R Johnston, I E Smith, et al.Scandinavian Journal of Immunology|May 16, 2013
Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseasesL Vargas, A Hamasy, B F Nore, et al.Oncology (Williston Park, N.Y.)|December 1, 2000
UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancerR K Gregory, S R Johnston, I E Smith, et al.Journal of Substance Abuse Treatment|January 1, 1992
A comparison study of treated and untreated pregnant and postpartum cocaine-abusing womenI E Smith, D Z Dent, C D Coles, et al.British Journal of Cancer|May 1, 1983
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancerA L Harris, M Dowsett, I E Smith, et al.Cancer Research|February 1, 1978
In vitro radiation response of cells from four human tumors propagated in immune-suppressed miceI E Smith, V D Courtenay, J Mills, et al.Breast (Edinburgh, Scotland)|October 13, 2015
Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumabB Yeo, K Kotsori, K Mohammed, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?J Bernhard, B Thürlimann, S F Schmitz, et al.European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter studyP Therasse, L Mauriac, M Welnicka-Jaskiewicz, et al.Pageof 32